Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 121 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Follow-Up Questions
Qui est le CEO de Kodiak Sciences Inc ?
Dr. Victor Perlroth est le Chairman of the Board de Kodiak Sciences Inc, il a rejoint l'entreprise depuis 2009.
Quelle est la performance du prix de l'action KOD ?
Le prix actuel de KOD est de $15, il a increased de 6.38% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Kodiak Sciences Inc ?
Kodiak Sciences Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Kodiak Sciences Inc ?
La capitalisation boursière actuelle de Kodiak Sciences Inc est de $792.3M
Est-ce que Kodiak Sciences Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Kodiak Sciences Inc, y compris 0 achat fort, 1 achat, 4 maintien, 6 vente et 0 vente forte
